TroFuse-005 Dual Survival Win Faces Safety Void and TROP2 Rival Race

Merck's Sacituzumab Tirumotecan Improves Survival in Endometrial Cancer

Merck announced positive results from the pivotal Phase 3 TroFuse-005 trial of sacituzumab tirumotecan (sac-TMT), an investigational TROP2-directed antibody-drug conjugate, for patients with advanced or recurrent endometrial cancer previously treated with platinum-based chemotherapy and anti-PD-1/L1 immunotherapy. The study met its dual primary endpoints, demonstrating a statistically significant and clinically meaningful improvement in overall survival (OS) and progression-free survival (PFS) compared to treatment of physician’s choice. Sac-TMT reduced the risk of death by 32% (HR=0.68), extending median OS by 6.9 months (19.0 vs. 12.1 months), and reduced the risk of disease progression or death by 41% (HR=0.59), extending median PFS by 3.3 months (7.2 vs. 3.9 months). The U.S. FDA has accepted a Biologics License Application for priority review based on these data.

• The TroFuse-005 trial demonstrated that sacituzumab tirumotecan significantly improved overall survival (OS) and progression-free survival (PFS) in patients with advanced or recurrent endometrial cancer. Sac-TMT extended median OS by 6.9 months (19.0 months vs. 12.1 months for TPC) with a 32% reduction in the risk of death (HR=0.68; 95% CI, 0.55-0.84; P<0.0001). It also extended median PFS by 3.3 months (7.2 months vs. 3.9 months for TPC) with a 41% reduction in the risk of disease progression or death (HR=0.59; 95% CI, 0.50-0.70; P<0.0001).
• Based on these robust Phase 3 results, the U.S. FDA has granted priority review to a Biologics License Application (BLA) for sacituzumab tirumotecan, setting a Prescription Drug User Fee Act (PDUFA) date of June 15, 2027. This regulatory advancement, coupled with sac-TMT being the first TROP2 ADC to demonstrate an overall survival improvement in this specific setting, positions it to potentially transform the treatment landscape for patients with limited options after prior platinum-based chemotherapy and anti-PD-1/L1 immunotherapy.
• The safety profile of sacituzumab tirumotecan in the TroFuse-005 trial was consistent with previously reported studies, showing no new safety signals. Treatment-related adverse events were predominantly low grade and manageable with supportive care and dose modifications, resulting in low discontinuation rates. This favorable safety profile, alongside Merck's extensive TroFuse clinical development program, which includes 18 ongoing global Phase 3 trials across various tumor types, underscores the company's commitment to advancing innovative solutions, particularly in women's cancers.

Challenges in Treating Advanced Endometrial Cancer After Prior Therapies

Advanced or recurrent endometrial cancer after prior systemic therapy is associated with poor prognosis, with five-year survival of only 10-20%. No standard subsequent-line therapy has been identified for recurrent or metastatic disease, and data on post-immunotherapy progression are lacking.

• Limited activity in biomarker-unselected and mismatch repair proficient disease: Response to immunotherapy has been less significant in other EC molecular types outside mismatch repair deficiency, with a limitation in biomarkers predictive of response to immunotherapy or available to examine for treatment selection, outside of mismatch repair deficiency. In a translational randomized phase II trial, no biomarkers for response have been identified.

• Absence of defined standard after prior chemoimmunotherapy: The combination of pembrolizumab and lenvatinib is the standard treatment if chemoimmunotherapy has not been used previously. If it has been, therapeutic strategy depends on the duration of platinum-free interval, and inclusion in a clinical trial should always be considered when the patient's performance status makes it possible.

• High toxicity burden requiring dose modification and discontinuation: In a single-center retrospective analysis of lenvatinib plus pembrolizumab, all patients experienced one or more adverse events, the most common of which were hypothyroidism (90%) and hypertension (83.3%). Among the 15 patients, 13 required lenvatinib dose reduction owing to adverse events, treatment was discontinued owing to adverse events in six patients, and one patient developed grade 4 interstitial pneumonia requiring intensive care. In an interim analysis of a multicentre, open-label, single-arm, phase 2 trial, serious treatment-related adverse events occurred in 16 (30%) patients, and one treatment-related death was reported (intracranial haemorrhage), with any-grade hypertension (31 [58%]), fatigue (29 [55%]), diarrhoea (27 [51%]), and hypothyroidism (25 [47%]), grade 3 hypertension (18 [34%]) and diarrhoea (four [8%]), and five (9%) patients discontinued study treatment because of treatment-related adverse events.

• Diminished efficacy on immune checkpoint inhibitor rechallenge: Median progression-free survival decreased from 11.0 months (95% confidence interval 8.7 to 19.0) with prior immune checkpoint inhibitor exposure to 6.0 months (95% confidence interval 4.0 to 16.0) with immune checkpoint inhibitor rechallenge, with objective response rate of 76% (22/29) with prior exposure and 52% (15/29) upon rechallenge.

TroFuse-005: Design, Endpoints, and Breakthrough Outcomes

The knowledge base does not have sufficient information to answer this question.

The Future of Sac-TMT: Expanding Across Tumor Types

Sacituzumab tirumotecan (sac-TMT) is under active investigation across multiple solid tumors beyond endometrial cancer, with development spanning urothelial carcinoma, non-small-cell lung cancer, breast cancer and gynecologic and gastrointestinal malignancies. Intervention models range from monotherapy to randomized comparisons against chemotherapy and combinations with pembrolizumab.

Sac-TMT's Breakthrough: A New Era for Advanced Endometrial Cancer

The recent announcement of positive Phase 3 results for sacituzumab tirumotecan (sac-TMT) marks a significant moment for patients battling advanced or recurrent endometrial cancer, particularly those who have exhausted prior lines of therapy including platinum-based chemotherapy and anti-PD-1/L1 immunotherapy. This patient population faces a grim prognosis, with limited effective options beyond existing chemotherapy regimens, which are often not curative, or combination therapies like temsirolimus and bevacizumab, which carry notable toxicities. The advent of immunotherapy has certainly transformed the landscape for specific subgroups, especially those with mismatch repair deficient (MMRd) tumors, but a substantial unmet need persists for patients progressing after these treatments.

Sac-TMT, a TROP2-directed antibody-drug conjugate, has demonstrated a compelling clinical benefit, significantly extending both overall survival and progression-free survival. This success underscores the growing importance of ADCs in oncology, leveraging a targeted antibody to deliver a potent cytotoxic payload directly to cancer cells, with the added advantage of a 'bystander effect' that can address tumor heterogeneity. The FDA's priority review status reflects the urgency and potential impact of this therapy.

However, as this promising agent moves towards approval, several considerations come into focus. While efficacy is clear, the safety profile, particularly the incidence of Grade ≥3 adverse events such as neutropenia and gastrointestinal issues observed with prior TROP2-directed ADCs in similar patient populations, will be critical for real-world adoption. Furthermore, while TROP2 is widely expressed in endometrial cancer, prior research suggests that TROP2 expression levels may not reliably predict response, indicating a need for further biomarker refinement to optimize patient selection. The evolving treatment paradigm for endometrial cancer, with the integration of immunotherapy into first-line settings and the emergence of other ADCs and targeted therapies, means sac-TMT will enter a dynamic competitive landscape. Establishing its optimal sequencing within the current and future treatment algorithms will be key to maximizing its clinical utility and market potential. This development not only offers a new lifeline for patients but also reinforces the strategic value of ADC platforms in tackling challenging solid tumors.